Commonwealth Equity Services
TRVI icon

Commonwealth Equity Services’s Trevi Therapeutics TRVI Stock Holding History

Commonwealth Equity Services’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15,000
Closed -$33K – 3801
2022
Q1 		$33K Buy
+15,000
New +$15.5K ﹤0.01% 3621

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Commonwealth Equity Services's TRVI Position: Q2 2022 in Review

Commonwealth Equity Services sold out of Trevi Therapeutics (TRVI) in Q2 2022, closing a stake of 15,000 shares — an estimated $33K sold.

Commonwealth Equity Services first reported a position in TRVI in Q1 2022 and held it in 1 quarter. The position peaked at $33K in Q1 2022. 32 funds tracked by Wall St. Rank hold TRVI as of Q2 2022.

  • Commonwealth Equity Services reported no remaining Trevi Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Commonwealth Equity Services sold 15,000 Trevi Therapeutics shares in Q2 2022, an estimated $33K.
  • Commonwealth Equity Services first reported a position in Trevi Therapeutics in Q1 2022 and held it in 1 quarter.
  • Commonwealth Equity Services's Trevi Therapeutics position peaked at $33K in Q1 2022.
  • 32 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2022.

Based on Commonwealth Equity Services's 13F filing for Q2 2022, filed 19 Jul 2022.